AVIR - Atea Pharmaceuticals, Inc.
About Atea Pharmaceuticals, Inc. (https://www.ateapharma.com)
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Jean-Pierre Sommadossi | Founder, Chairman, Chief Executive Officer & President | 1956 | $1,125,584 USD |
| Janet J. Hammond | Chief Development Officer | 1960 | $870,794 USD |
| Andrea J. Corcoran | Chief Financial Officer, Executive Vice President of Legal & Secretary | 1962 | $810,818 USD |
| Maria Arantxa Horga | Chief Medical Officer | 1968 | $747,102 USD |
| John F. Vavricka | Chief Commercial Officer | 1963 | $634,437 USD |
| Wayne Foster | Executive Vice President of Finance & Chief Accounting Officer | 1969 | $580,463 USD |
| Adel Moussa | Executive Vice President of Chemistry | – | – |
| Jonae R. Barnes | Senior Vice President of Investor Relations & Corporate Communications | – | – |
| Keith Pietropaolo | Executive Vice President of Clinical Sciences & Project Management | – | – |
| Xiao-Jian Zhou | Executive Vice President of Early Stage Development | – | – |